Delcasertib is an antiviral agent primarily investigated for its potential in treating infections caused by picornaviruses, which include viruses responsible for the common cold, certain types of meningitis, and other respiratory illnesses. It functions by inhibiting viral replication through targeting the viral 3C protease, an enzyme essential for the processing of viral polyproteins during the life cycle of the virus. This inhibition prevents the virus from producing functional proteins, thereby halting its spread within the host. The compound has been studied in clinical settings for the treatment of enterovirus infections, particularly in immunocompromised patients who are at higher risk of severe or prolonged disease. Due to its mechanism of action, delcasertib shows promise in addressing infections with limited treatment options, especially where supportive care is currently the standard. Research continues to explore its efficacy, safety, and potential use in combination therapies against resistant or persistent viral strains.